R&D has far exceeded PPE investment in our megacap companies. Firms share next to nothing about R&D with investors while regulators drag their feet. This leads to fantasy valuations and huge informational advantages for firm management.
R&D has far exceeded PPE investment in our megacap companies. Firms share next to nothing about R&D with investors while regulators drag their feet. This leads to fantasy valuations and huge informational advantages for firm management.
Share this Article
Comment on this Article
Recommended
Please to comment